Corbus Pharmaceuticals Holdings, Inc. Stock
Stocks
CRBP
US21833P3010
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.680 USD | +0.21% |
|
+4.65% | +18.92% |
| Market Cap | 179M 157M 145M 134M 254M 17.1B 258M 1.73B 679M 8.43B 673M 659M 29B | P/E 2026 * |
-2.08x | P/E 2027 * | -1.83x |
|---|---|---|---|---|---|
| Enterprise Value | 179M 157M 145M 134M 254M 17.1B 258M 1.73B 679M 8.43B 673M 659M 29B | EV / Sales 2026 * |
161x | EV / Sales 2027 * | 74.7x |
| Free-Float |
98.92% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Corbus Pharmaceuticals Holdings, Inc.
| 1 day | +0.21% | ||
| 1 week | +4.65% | ||
| Current month | +3.20% | ||
| 1 month | +25.71% | ||
| 3 months | -1.22% | ||
| 6 months | +16.49% | ||
| Current year | +18.92% |
| 1 week | 8.95 |  | 9.88 |
| 1 month | 7.74 | | 9.88 |
| Current year | 7.12 | | 12.88 |
| 1 year | 7.12 | | 20.56 |
| 3 years | 3.03 | | 61.9 |
| 5 years | 2.11 | | 61.9 |
| 10 years | 2.11 | | 323.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 51 | 11/04/2014 |
Sean Moran
DFI | Director of Finance/CFO | 68 | 11/04/2014 |
Leonardo Nicacio
CTO | Chief Tech/Sci/R&D Officer | 48 | 06/07/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Yuval Cohen
BRD | Director/Board Member | 51 | 11/04/2014 |
John Jenkins
BRD | Director/Board Member | 68 | 05/06/2018 |
Rachelle Jacques
CHM | Chairman | 54 | 15/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-10 | Sell | Director | -2,412 | 0.0130% | ||
| 06-10 | Sell | Director | -4,800 | 0.0259% | ||
| 06-10 | Sell | Director | -2,026 | 0.0109% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.21% | +4.65% | +15.79% | +25.39% | 179M | |
| -4.14% | -8.06% | +57.35% | +117.24% | 54.63B | |
| +1.84% | -0.66% | +75.79% | +93.87% | 54.88B | |
| -2.24% | +3.59% | +19.60% | +466.72% | 25.06B | |
| -1.60% | -6.21% | -19.69% | -14.84% | 23.14B | |
| +2.43% | +1.06% | +47.70% | -0.11% | 19.88B | |
| -3.19% | 0.00% | +33.99% | -26.87% | 17.55B | |
| -6.84% | +2.18% | +195.12% | +357.18% | 16.5B | |
| -1.05% | +1.16% | +25.08% | +196.28% | 14.2B | |
| +8.74% | +3.51% | +53.81% | - | 15.36B | |
| Average | -0.58% | +0.19% | +50.46% | +134.98% | 24.14B | |
| Weighted average by Cap. | -0.91% | -1.45% | +55.01% | +137.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.11M 973K 898K 829K 1.57M 106M 1.6M 10.72M 4.21M 52.2M 4.17M 4.08M 180M | 2.4M 2.1M 1.94M 1.79M 3.4M 229M 3.45M 23.16M 9.08M 113M 9.01M 8.81M 388M |
| Net income | -97.64M -85.54M -78.87M -72.88M -138M -9.31B -140M -942M -370M -4.59B -367M -359M -15.79B | -123M -108M -99.15M -91.61M -174M -11.71B -177M -1.18B -465M -5.77B -461M -451M -19.84B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/07/26 | $9.680 | +0.21% | 216,351 |
| 09/07/26 | $9.660 | +1.15% | 230,231 |
| 08/07/26 | $9.550 | +1.81% | 490,996 |
| 07/07/26 | $9.380 | +4.22% | 528,799 |
| 06/07/26 | $9.000 | -2.70% | 263,617 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRBP Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
